Investigational drug · Phase 2
PM647a
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alpha-1 Antitrypsin Deficiency, Alpha-1 Antitrypsin Deficiency-associated Lung Disease, Alpha-1 Antitrypsin Deficiency (AATD).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "PM647a"
First trial start
2026
Oct 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PM647a", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alpha-1 Antitrypsin Deficiency
- Alpha-1 Antitrypsin Deficiency-associated Lung Disease
- Alpha-1 Antitrypsin Deficiency (AATD)
- AATD
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "PM647a" as an intervention, largest first.
- A Study of the Safety and Efficacy of Prime Editing (PM647a) in Participants With Alpha-1 Antitrypsin DeficiencyNot yet recruiting
Prime Medicine, Inc.Industry
NCT07887347 · 54 participants (planned) · Start Oct 2026 · Primary completion Dec 2028
Drug: PM647a · For: Alpha-1 Antitrypsin Deficiency; Alpha-1 Antitrypsin Deficiency-associated Lung Disease; Alpha-1 Antitrypsin Deficiency (AATD) and 1 more
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Alpha-1 Antitrypsin Deficiency
- WVE-006Phase 21 trial
Wave Life Sciences USA, Inc. · Alpha-1 Antitrypsin Deficiency
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.